BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Butterworth RF, Kircheis G, Hilger N, McPhail MJW. Efficacy of l-Ornithine l-Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Exp Hepatol. 2018;8:301-313. [PMID: 30302048 DOI: 10.1016/j.jceh.2018.05.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Butterworth RF, McPhail MJW. L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses. Drugs. 2019;79:31-37. [PMID: 30706425 DOI: 10.1007/s40265-018-1024-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
2 Hey P, Gow P, Testro AG, Apostolov R, Chapman B, Sinclair M. Nutraceuticals for the treatment of sarcopenia in chronic liver disease. Clin Nutr ESPEN 2021;41:13-22. [PMID: 33487256 DOI: 10.1016/j.clnesp.2020.11.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
3 Butterworth RF. Hepatic Encephalopathy. In: Arias IM, Alter HJ, Boyer JL, Cohen DE, Shafritz DA, Thorgeirsson SS, Wolkoff AW, editors. The Liver. Wiley; 2020. pp. 615-29. [DOI: 10.1002/9781119436812.ch48] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications. Clin Mol Hepatol 2020;26:83-127. [PMID: 31918536 DOI: 10.3350/cmh.2019.0010n] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
5 Canbay A, Sowa JP. L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease. Drugs 2019;79:39-44. [PMID: 30706422 DOI: 10.1007/s40265-018-1020-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
6 Butterworth RF. L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle. Can J Gastroenterol Hepatol 2019;2019:8182195. [PMID: 31183339 DOI: 10.1155/2019/8182195] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
7 Butterworth RF. Ammonia Removal by Metabolic Scavengers for the Prevention and Treatment of Hepatic Encephalopathy in Cirrhosis. Drugs R D 2021;21:123-32. [PMID: 33890246 DOI: 10.1007/s40268-021-00345-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Campion D, Giovo I, Ponzo P, Saracco GM, Balzola F, Alessandria C. Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis. World J Hepatol 2019; 11(6): 489-512 [PMID: 31293718 DOI: 10.4254/wjh.v11.i6.489] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
9 Hoilat GJ, Suhail FK, Adhami T, John S. Evidence-based approach to management of hepatic encephalopathy in adults. World J Hepatol 2022; 14(4): 670-681 [DOI: 10.4254/wjh.v14.i4.670] [Reference Citation Analysis]
10 Tranah TH, Shawcross DL. The rise and fall and rise again of ammonia as a therapeutic target in HE. Hepatology 2022;75:1078-80. [PMID: 34995377 DOI: 10.1002/hep.32319] [Reference Citation Analysis]
11 Tapper EB, Ufere NN, Huang DQ, Loomba R. Review article: current and emerging therapies for the management of cirrhosis and its complications. Aliment Pharmacol Ther 2022;55:1099-115. [PMID: 35235219 DOI: 10.1111/apt.16831] [Reference Citation Analysis]
12 Mehtani R, Garg S, Kajal K, Soni SL, Premkumar M. Neurological monitoring and sedation protocols in the Liver Intensive Care Unit. Metab Brain Dis 2022. [PMID: 35460476 DOI: 10.1007/s11011-022-00986-7] [Reference Citation Analysis]
13 Strebel H, Haller B, Sohn M, Schepp W, Gundling F. Role of Brain Biomarkers S-100-Beta and Neuron-Specific Enolase for Detection and Follow-Up of Hepatic Encephalopathy in Cirrhosis before, during and after Treatment with L-Ornithine-L-Aspartate. GE Port J Gastroenterol 2020;27:391-403. [PMID: 33251288 DOI: 10.1159/000507225] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Butterworth RF. Beneficial effects of L-ornithine L-aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: a systematic review with meta-analysis. Metab Brain Dis 2020;35:75-81. [PMID: 31338724 DOI: 10.1007/s11011-019-00463-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
15 Alsahhar JS, Rahimi RS. Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy. Current Opinion in Gastroenterology 2019;35:145-54. [DOI: 10.1097/mog.0000000000000527] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Rose CF, Amodio P, Bajaj JS, Dhiman RK, Montagnese S, Taylor-Robinson SD, Vilstrup H, Jalan R. Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. J Hepatol. 2020;73:1526-1547. [PMID: 33097308 DOI: 10.1016/j.jhep.2020.07.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
17 Butterworth RF, Canbay A. Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease. Dig Dis 2019;37:63-8. [PMID: 30016770 DOI: 10.1159/000491429] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
18 Mogilnicka I, Bogucki P, Ufnal M. Microbiota and Malodor-Etiology and Management. Int J Mol Sci 2020;21:E2886. [PMID: 32326126 DOI: 10.3390/ijms21082886] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
19 Bajaj JS, Lauridsen M, Tapper EB, Duarte-rojo A, Rahimi RS, Tandon P, Shawcross DL, Thabut D, Dhiman RK, Romero-gomez M, Sharma BC, Montagnese S. Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus. Am J Gastroenterol 2020;115:989-1002. [DOI: 10.14309/ajg.0000000000000603] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
20 Caraceni P, Vargas V, Solà E, Alessandria C, de Wit K, Trebicka J, Angeli P, Mookerjee RP, Durand F, Pose E, Krag A, Bajaj JS, Beuers U, Ginès P; Liverhope Consortium. The Use of Rifaximin in Patients With Cirrhosis. Hepatology 2021;74:1660-73. [PMID: 33421158 DOI: 10.1002/hep.31708] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 20.0] [Reference Citation Analysis]
21 Butterworth RF. Hepatic Encephalopathy in Cirrhosis: Pathology and Pathophysiology. Drugs. 2019;79:17-21. [PMID: 30706423 DOI: 10.1007/s40265-018-1017-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
22 Kircheis G, Lüth S. Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy. Drugs 2019;79:23-9. [PMID: 30706424 DOI: 10.1007/s40265-018-1023-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
23 Jain A, Sharma BC, Mahajan B, Srivastava S, Kumar A, Sachdeva S, Sonika U, Dalal A. L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial. Hepatology 2022;75:1194-203. [PMID: 34822189 DOI: 10.1002/hep.32255] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
24 Chakravarthy MV, Neutel J, Confer S, Zhao P, Tatsuta N, Rebello S, Comb WC, Hamill M, Tramontin T, Carroll S, Afeyan R, Sanyal AJ. Safety, Tolerability, and Physiological Effects of AXA1665, a Novel Composition of Amino Acids, in Subjects With Child-Pugh A and B Cirrhosis. Clin Transl Gastroenterol 2020;11:e00222. [PMID: 32955200 DOI: 10.14309/ctg.0000000000000222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]